Viridian Therapeutics Financials - Benzinga

Viridian Therapeutics Inc

VRDNNASDAQ

Trade with Public

Trade with Public

$22.06

0.482.22%

Últ. Act.: Sep 22, 3:21 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Viridian Therapeutics Financials

Viridian Therapeutics (VRDN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of $(1.00) per share

Benzinga Newsdesk

Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED)

U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, following Friday's mixed close.

Rishabh Mishra

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.

Avi Kapoor

PRO
Viridian Therapeutics Q1 EPS $(0.90) Beats $(1.05) Estimate, Sales $141.000K Beat $27.500K Estimate

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.05) by 14.29 percent. This is a 3.45 percent decrease over losses of $(0.87) per share

Benzinga Newsdesk

Earnings Breakdown: Viridian Therapeutics Q4

Benzinga Insights

PRO
Viridian Therapeutics Q4 EPS $(1.08) Misses $(0.93) Estimate, Sales $132.000K

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.76 percent. This is a 33.33 percent decrease over losses of $(0.81) per

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved